



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

1 16 July 2020
2 EMA/198149/2020
3 Veterinary Medicines

4 Union Product Database (UPD) Access Policy

5 Veterinary Medicinal Products

6 POLICY/no 0082
7 Status: Consultation
8 Effective date: tbc
9 Review date: tbc
10 Supersedes: n/a
11



12	Table of contents	
13	Executive Summary	3#
14	1. Scope	3#
15	2. Policy statement	4#
16	3. Objectives	4#
17	4. Characteristics of the policy	4#
18	4.1. Union Product Database and medicinal products for veterinary use.....	4#
19	4.2. Access to Union Product Database	5#
20	4.2.1. Stakeholder groups.....	5#
21	4.2.2. General principles.....	5#
22	4.2.3. Personal Data Protection	6#
23	4.2.4. Methods of providing access to product data held in UPD.....	7#
24	4.2.5. Detailed description of access to product data held in UPD, by Stakeholder	7#
25	5. Entry into force of the UPD access Policy	10#
26	Annexes	11#
27		

28 **Executive Summary**

29 The European Medicines Agency (hereafter referred to as “the Agency”) and the Member States’
30 competent authorities collectively comprise the European Union (EU) regulatory network. The
31 network’s responsibilities are the protection and promotion of public and animal health and the
32 environment through the evaluation and supervision of medicines.

33 Regulation (EU) 2019/6 of the European Parliament and of the Council of 11 December 2018 on
34 veterinary medicinal products and repealing Directive 2001/82/EC (‘the VMP Regulation’), was adopted
35 on 11 December 2018, entered into force on 28 January 2019 and will become applicable from 28
36 January 2022, following a 3-year implementation period. The VMP Regulation contains new measures
37 for increasing the availability and safety of veterinary medicines, enhances EU action against
38 antimicrobial resistance and will modernise the existing rules on the authorisation and use of
39 veterinary medicines in the EU.

40 The VMP Regulation mandates that the Agency establish and, in collaboration with the Member States,
41 maintain, a Union database on veterinary medicinal products (UPD), containing information on
42 veterinary medicinal products authorised within the Union, homeopathic veterinary medicinal products
43 registered within the Union, veterinary medicinal products exempted in a Member State from the
44 marketing authorisation requirements, and parallel traded products. This database shall also register
45 the annual volume of sales, information on the availability for each veterinary medicinal product and
46 variations not requiring assessment for authorised veterinary medicinal products.

47 Furthermore, by means of implementing acts, the European Commission (‘the Commission’) will adopt
48 the necessary measures and practical arrangements laying down detailed specifications to be
49 implemented in order to fulfil the requirements of the VMP Regulation. In this context, it is mandated
50 that a detailed access policy be drawn up and applied by the Agency, in collaboration with the
51 competent authorities and the Commission, and in consultation with marketing authorisation holders,
52 before the UPD becomes operational. It should enable actors to perform their obligations as provided
53 for in the VMP Regulation, while protecting commercially confidential information and personal data. It
54 should therefore provide different levels of access to the UPD processes.

55 **1. Scope**

56 This Access Policy defines the overall principles for providing access to veterinary medicinal product
57 information held in the UPD in line with the EU legislative framework, considering that the interest in
58 and the use of the data may vary between stakeholders.

59 The policy has been drafted with the aim of providing transparency and visibility of information on
60 veterinary medicinal products while protecting commercially confidential information, as required in the
61 VMP Regulation. Requirements to protect personal data based on Regulation (EU) 2016/679 and
62 Regulation (EU) 2018/1725 are reflected in the policy accordingly.

63 ‘Veterinary medicinal products’ in this policy include

- 64 • authorised veterinary medicinal products;
- 65 • registered homeopathic veterinary medicinal products;
- 66 • veterinary medicinal products exempted in a Member State from the marketing authorisation
67 requirements under Article 5(6); and
- 68 • parallel traded products

69 The VMP Regulation defines the level of UPD access as follows (Article 56):

- 70 1. *The competent authorities, the Agency and the Commission shall have full access to the*
71 *information in the product database.*

- 72 2. *Marketing authorisation holders¹ shall have full access to the information in the product*
73 *database as regards their marketing authorisations.*
- 74 3. *The general public shall have access to information in the product database, without the*
75 *possibility to change the information therein, as regards the list of the veterinary medicinal*
76 *products, the summary of product characteristics, package leaflets and, after the deletion of*
77 *any commercially confidential information by the competent authority, the assessment reports.*

78 The description of individual scenarios and veterinary medicinal products are further outlined in
79 Annex A.

80 **2. Policy statement**

81 The following aspects are addressed in this policy:

- 82 • Objectives of the policy.
- 83 • Characteristics of the policy.
- 84 • Date of coming into effect of the policy.

85

86 **3. Objectives**

87 This access policy has been developed with the goal of facilitating the maintenance of and accessibility
88 to information on veterinary medicinal products in the EU, within the overall aim of promoting and
89 protecting animal and public health and the environment.

90 Furthermore, the access policy aims to meet the EU principles of transparency and openness and to
91 ensure compliance with EU personal data protection legislation. The following objectives should be
92 met, by providing proactive access to product information on veterinary medicinal products:

- 93 1. Increasing availability of and access to information on veterinary medicinal products authorised to
94 treat and prevent animal diseases in the EU for veterinarians, farmers and pet owners and any
95 other interested parties;
- 96 2. Supporting the functioning of the internal EU market for veterinary medicinal products;
- 97 3. Improving transparency of veterinary medicinal products used in the EU;
- 98 4. Strengthening the decision making for the Commission, competent authorities and marketing
99 authorisation holders by providing access to data analytics and reports;
- 100 5. Simplifying the regulatory environment and reducing the administrative burden by giving
101 marketing authorisation holders and competent authorities access to the functionalities of the
102 variations without assessment module of the UPD.

103

104 **4. Characteristics of the policy**

105 **4.1. Union Product Database**

106 The UPD comprises a range of functions required for the administration and quality management of
107 information related to veterinary medicinal products and its secure electronic transmission.
108 Additionally, the UPD offers a specific mechanism for handling a change to the data that occurs when

¹ 'Marketing authorisation holder' is defined in this policy to include: holder of the marketing authorisation for a veterinary medicinal product, of the registration for a homeopathic veterinary medicinal product, of the exemption for products allowed for use in accordance with Article 5(6) of Regulation (EU) 2019/6 or of the approval for parallel trade

109 such changes are based on a variation that does not require assessment. A set of components has
110 been designed, enhanced or reutilised to support such functionalities:

- 111 • **Access management component** which manages the control of access to data or
112 functionalities and ensures that all stakeholders have the appropriate access to the resources
113 provided by the UPD and the proper permissions to perform actions in the UPD.
- 114 • **Data and document submission component** which manages the requests for submission to
115 the UPD of data and documents relating to new veterinary medicinal products in order to
116 create a new dataset, variations and other post-authorisation changes to the datasets already
117 existing in the UPD for veterinary medicinal products.
- 118 • **Application programming interface** for the exchange of data and documents with the
119 systems used by marketing authorisation holders, competent authorities, the Agency and the
120 Commission.
- 121 • **UPD portal** which, with the use of data publishing, data searching, viewing and exporting, as
122 well as data analytics, presents information to users and makes certain features available to
123 them in accordance with their access rights (objective 4).
- 124 • **Data and document repository component** which manages all data and documents that
125 enter into the UPD.
- 126 • **Component to manage variations that do not require assessment component** which
127 allows the marketing authorisation holder to submit a variation that does not require
128 assessment and allows the relevant competent authority or the Commission, as applicable, to
129 be notified and to approve or reject such variations prior to the update in the UPD, to update
130 the dataset accordingly and to store and update related documentation (objective 5).
- 131 • **General public module** which is part of the UPD portal and allows the general public to
132 search and view all publicly available data and documents on veterinary medicinal products
133 referred to in Article 56 of the VMP Regulation (objectives 1, 2 and 3).

134 Different levels of access to these components must be defined and implemented to ensure that the
135 different stakeholders interacting with the UPD can access the information necessary to fulfil their
136 responsibilities as outlined in the VMP Regulation and related Implementing Acts or enjoy their right to
137 access information.

138

139 **4.2. Access to Union Product Database**

140 **4.2.1. Stakeholder groups**

141 The stakeholders being granted access to UPD data can be grouped as follows:

- 142 • **The Commission, competent authorities and the Agency;**
- 143 • **Marketing authorisation holders**, including relevant external service providers;
- 144 • **General Public:** persons or organisations, other than the two groups referred to above.

145

146 **4.2.2. General principles**

147 Veterinary medicinal products are recorded in the UPD as derived from legal obligations placed on
148 competent authorities and marketing authorisation holders.

149 The VMP Regulation gives the widest possible access to veterinary medicinal product data and to the
150 related documents while protecting certain public and private interests, such as personal data and
151 commercially confidential information in accordance with Regulation (EC) No 1049/2001.

152 The data elements for veterinary medicinal product data stored in the UPD are defined in the
153 *Commission Implementing Regulation (EU) laying down the necessary measures and practical
154 arrangements for the Union product database on veterinary medicinal products²* ('the Implementing
155 Regulation') and further detailed in *Product Management Services – Implementation of Regulation
156 2019/6 standards for the identification of medicinal products in Europe* ('the EU Vet Implementation
157 Guide').

158 Access is defined based on the stakeholder's interests and needs as well as the requirement to comply
159 with EU personal data protection legislation (Regulation (EU) 679/2016 or General Data Protection
160 Regulation (GDPR)). The protection of personal data is a fundamental right of Europeans. The access is
161 further defined at different levels considering that due to the nature of the information not all data
162 elements can be disclosed to avoid identification of data subjects or dissemination of commercially
163 confidential information.

164 Annex A lists all UPD veterinary medicinal product data elements and outlines which can be accessed
165 by the different stakeholder groups, based on the access levels described in Table 1.

166 **Table 1.** Description of access levels

Access Level	Description
Level 1	Public subset of veterinary medicinal product data elements with focus on the General Public user group.
Level 2	Extended subset of veterinary medicinal product data elements with focus on the marketing authorisation holder user group to fulfil their legal responsibilities for their own products, which have been recorded in the database by the authorities.
Level 3	All veterinary medicinal product data elements without restrictions with focus on the competent authorities, the Commission and the Agency, taking into account their roles and responsibilities to protect public and animal health and the environment.

167

168 **4.2.3. Personal Data Protection**

169 The Agency, competent authorities and marketing authorisation holders are all responsible for ensuring
170 confidentiality of veterinary medicinal product data and protecting personal data by implementing
171 appropriate technical and organisational measures to protect information and personal data processed
172 against unauthorised or unlawful access, disclosure, dissemination, alteration, or destruction or
173 accidental loss in accordance with the applicable law on personal data protection.

174 Personal data shall mean any information relating to an identified or identifiable natural person ('data
175 subject'); an identifiable natural person is one who can be identified, directly or indirectly, in particular
176 by reference to an identifier such as a name, an identification number, location data, an online
177 identifier or to one or more factors specific to the physical, physiological, genetic, mental, economic,
178 cultural or social identity of that natural person; (Article 3(1) of Regulation (EU) 2018/1725).

² Number and date to be added following adoption of the Implementing Regulations

179 For the Agency, the provisions set out in Regulation (EU) 2018/1725 apply; for competent authorities
 180 and marketing authorisation holders, the rules set out in Regulation (EU) No 679/2016 (GDPR) apply.

181 **4.2.4. Methods of providing access to veterinary medicinal product**
 182 **information held in UPD**

183 Access to UPD data is provided through query and data retrieval functions based on the UPD system
 184 components described in section 4.1. Table 2 provides an overview of the UPD system components
 185 applied to provide access to UPD data for each stakeholder group and outlines the overall format of the
 186 data outputs.

187 **Table 2.** UPD system components with UPD product data outputs by stakeholder group

UPD System Component	Data Outputs
Stakeholder: the Commission, competent authorities and the Agency	
Data and document submission portal	Structured electronic content (XML and JSON formats) and unstructured content (e.g. PDF)
Application programming interface	Structured electronic content (XML and JSON formats) and unstructured content (e.g. PDF)
UPD portal	Web page(s) in HTML format; showing all product data and providing search functions
Stakeholder: marketing authorisation holders	
Data and document submission portal	Structured electronic content (XML and JSON formats) and unstructured content (e.g. PDF)
Application programming interface	Structured electronic content (XML and JSON formats) and unstructured content (e.g. PDF)
UPD portal	Web page(s) in HTML format; showing only data in accordance with their access rights and providing search functions
Stakeholder: General Public	
General Public Module	Web page(s) in HTML format; showing only the subset of data that is available to the public and providing search functions

188 **4.2.5. Detailed description of access to veterinary medicinal product data**
 189 **held in UPD, by Stakeholder**

190 **4.2.5.1. The Commission, competent authorities and the Agency**

191 **4.2.5.1.1. Veterinary medicinal products in UPD**

192 In accordance with the VMP Regulation, the competent authorities, the Agency and the Commission
 193 shall have full access to the information in the UPD.

194 **Table 3.** Access to UPD data by the competent authorities, the Agency and the Commission

Stakeholder	Access Level	Access Type
<ul style="list-style-type: none"> Competent authorities Agency The Commission 	<ul style="list-style-type: none"> UPD Level 3: <ul style="list-style-type: none"> All data elements for veterinary medicinal products reported to UPD (for details refer to Annex A) 	Authorised personnel only

195 **4.2.5.1.2. Methods of access**

196 A description of how access is provided to these stakeholders including the main data outputs is given
197 in Section 4.2.4

198 **4.2.5.1.3. Access authorisation**

199 Access is granted to authorised personnel of the Commission, the Agency and competent authorities.
200 The identification of 'authorised personnel' is detailed in the **UPD registration process** described in
201 the registration guide³. External service providers are also considered "authorised personnel" and their
202 access rights are administrated by the relevant organisation on whose behalf access is granted.

203 **4.2.5.1.4. Personal data protection requirements**

204 Data access and provision is based on a defined veterinary medicinal product data set (Level 3) in
205 compliance with the VMP Regulation. A Privacy Statement⁴ is included on the UPD Portal, explaining in
206 detail how personal data are processed. The Agency is also operating a procedure for access and
207 rectification in line with the aforementioned Regulation.

208 **4.2.5.2. Marketing authorisation holders**

209 **4.2.5.2.1. Veterinary medicinal products in the UPD**

210 In accordance with the VMP Regulation, the marketing authorisation holders⁵ shall have full access to
211 the information in the UPD as regards their products.

212 **Table 4.** Access to UPD data by marketing authorisation holders

Stakeholder	Access Level	Access Type
<ul style="list-style-type: none"> Marketing Authorisation Holders 	<ul style="list-style-type: none"> UPD Level 2: <ul style="list-style-type: none"> Subset of data elements for veterinary medicinal products reported to UPD (for details refer to Annex A) 	Authorised Personnel only

213 **4.2.5.2.2. Methods of access**

214 A description of how access is provided to these stakeholders including the main data outputs is given
215 in Section 4.2.4

³ The registration guide is being developed will be published before the launch of the UPD.

⁴ The Privacy Statement will be published together with the Access Policy document

⁵ Companies that are part of the same corporation or group of companies are considered as a single MAH.

216 **4.2.5.2.3. Access authorisation**

217 Access is granted to authorised personnel of the marketing authorisation holders. The identification of
218 'authorised personnel' is detailed in the UPD registration process described in the registration guide³.
219 External service providers are also considered "authorised personnel" and their access rights are
220 administrated by the relevant organisation on whose behalf access is granted.

221 **4.2.5.2.4. Personal data protection requirements**

222 Data access and provision is based on a defined veterinary medicinal product data set (Level 2) in
223 compliance with the VMP Regulation. A Privacy Statement⁶ is included on the UPD Portal, explaining in
224 detail how personal data are processed. The Agency is also operating a procedure for access and
225 rectification in line with the aforementioned Regulation.

226 **4.2.5.3. General public**

227 **4.2.5.3.1. Report of veterinary medicinal product**

228 In accordance with the VMP Regulation, the general public shall have access to information in the UPD,
229 without the possibility to change the information therein, as regards the list of the veterinary medicinal
230 products, the summary of product characteristics, package leaflets and, after the deletion of any
231 commercially confidential information by the competent authority, assessment reports.

232 **Table 5.** Access to UPD data by general public

Stakeholder	Access Level	Access Type
<ul style="list-style-type: none">General public	<ul style="list-style-type: none">UPD Level 1:<ul style="list-style-type: none">Subset of data elements for veterinary medicinal products reported to UPD (for details refer to Annex A)	Not required/controlled

233 **4.2.5.3.2. Methods of access**

234 A description of how access is provided to these stakeholders including the main data outputs is given
235 in Section 4.2.4

236 **4.2.5.3.3. Access authorisation**

237 No registration, authorisation or authentication shall be required for access to publicly available
238 information.

239 **4.2.5.3.4. Personal data protection requirements**

240 Data access and provision is based on a defined veterinary medicinal product data set (Level 1) in
241 compliance with the VMP Regulation. A Privacy Statement⁷ is included on the UPD Portal, explaining in
242 detail how personal data are processed. The Agency is also operating a procedure for access and
243 rectification in line with the aforementioned Regulation.

244

⁶ The Privacy Statement will be published together with the Access Policy document.

⁷ The Privacy Statement will be published together with the Access Policy document.

245 **5. Entry into force of the UPD access policy**

246 This access policy will enter into force as soon as it is approved.

247

248

249

250 Amsterdam, <DD Month YYYY>

251

252 Guido Rasi

253 Executive Director

254

255 **Annexes**

256 **Annex A – Product data elements accessible by stakeholder group**

257 RCUD = Read, Create, Update, Delete

258 Y/N = yes, no

259

UPD fields ⁸	Level 3												Level 2				Level 1			
	RCUD = Read, Create, Update, Delete																			
	Commission				Competent Authorities				Agency				Marketing authorisation holders				Public			
	R	C	U	D	R	C	U	D	R	C	U	D	R	C	U ⁽¹⁾	D	R	C	U	D
Product Domain	Y	N	N	N	Y	Y	N	N	Y	Y	N	N	Y	N	N	N	Y	N	N	N
Product Category	Y	N	N	N	Y	Y	N	N	Y	Y	N	N	Y	N	N	N	Y	N	N	N
Product Name	Y	N	N	N	Y	Y	Y	N	Y	Y	Y	N	Y	N	N	N	Y	N	N	N
Active Substance(s)	Y	N	N	N	Y	Y	Y	N	Y	Y	Y	N	Y	N	N	N	Y	N	N	N
Strength/Composition	Y	N	N	N	Y	Y	Y	N	Y	Y	Y	N	Y	N	N	N	Y	N	N	N
Manufacturing Sites	Y	N	N	N	Y	Y	Y	N	Y	Y	Y	N	Y	N	N	N	Y ⁽²⁾	N	N	N
Operation type (for manufacturing site)	Y	N	N	N	Y	Y	Y	N	Y	Y	Y	N	Y	N	N	N	Y ⁽²⁾	N	N	N
Dates of Placing on the Market	Y	N	N	N	Y	Y	Y	N	Y	Y	Y	N	Y	Y ⁽⁶⁾	N	N	Y	N	N	N
Documents (SPC, PL, PuAR) ⁹	Y	N	N	N	Y	Y ⁽⁵⁾	Y ⁽⁵⁾	N	Y	Y	Y	N	Y	N	N	N	Y	N	N	N
Product Owner	Y	N	N	N	Y	Y	Y	N	Y	Y	Y	N	Y	N	N	N	Y	N	N	N
Annual Volume of Sales	Y	N	N	N	Y	N	N	N	Y	N	N	N	Y ⁽⁶⁾	Y ⁽⁶⁾	Y ⁽⁶⁾	N	N	N	N	N
Date of Availability Status	Y	N	N	N	Y	Y	Y	N	Y	Y	Y	N	Y	Y ⁽⁶⁾	Y ⁽⁶⁾	N	Y	N	N	N

⁸ The available information in the data fields depends on the authorisation procedure type of veterinary medicinal product (authorised, registered homeopathic, Art. 5(6) exemption or parallel traded product)

⁹ The document types are: Summary of Product Characteristics, package leaflet and public assessment report

UPD fields ⁸	Level 3												Level 2				Level 1			
	RCUD = Read, Create, Update, Delete																			
	Commission				Competent Authorities				Agency				Marketing authorisation holders				Public			
	R	C	U	D	R	C	U	D	R	C	U	D	R	C	U ⁽¹⁾	D	R	C	U	D
Availability Status	Y	N	N	N	Y	Y	Y	N	Y	Y	Y	N	Y	Y ⁽⁶⁾	Y ⁽⁶⁾	N	Y	N	N	N
Authorisation Status	Y	N	N	N	Y	Y	Y	N	Y	Y	Y	N	Y	N	Y ⁽⁶⁾	N	Y ⁽³⁾	N	N	N
Date of Authorisation Status Change	Y	N	N	N	Y	Y	Y	N	Y	Y	Y	N	Y	N	Y ⁽⁶⁾	N	Y	N	N	N
Source Wholesale Distributor	Y	N	N	N	Y	Y	Y	N	Y	Y	Y	N	Y	N	N	N	Y	N	N	N
Destination Wholesale Distributor	Y	N	N	N	Y	Y	Y	N	Y	Y	Y	N	Y	N	N	N	Y	N	N	N
Permanent Identification Number	Y	N	N	N	Y	N	N	N	Y	N	N	N	Y	N	N	N	Y	N	N	N
Product Identification Number	Y	N	N	N	Y	Y	Y	N	Y	Y	Y	N	Y	N	N	N	Y	N	N	N
Route of Administration	Y	N	N	N	Y	Y	Y	N	Y	Y	Y	N	Y	N	N	N	Y	N	N	N
Pharmaceutical Form	Y	N	N	N	Y	Y	Y	N	Y	Y	Y	N	Y	N	N	N	Y	N	N	N
Target species	Y	N	N	N	Y	Y	Y	N	Y	Y	Y	N	Y	N	N	N	Y	N	N	N
ATCvet Code	Y	N	N	N	Y	Y	Y	N	Y	Y	Y	N	Y	N	N	N	Y	N	N	N
Withdrawal Period	Y	N	N	N	Y	Y	Y	N	Y	Y	Y	N	Y	N	N	N	Y	N	N	N
PSMF Number	Y	N	N	N	Y	Y	Y	N	Y	Y	Y	N	Y	N	N	N	Y	N	N	N
PSMF Location	Y	N	N	N	Y	Y	Y	N	Y	Y	Y	N	Y	N	N	N	Y	N	N	N
QPPV Name	Y	N	N	N	Y	Y	Y	N	Y	Y	Y	N	Y ⁽⁶⁾	N	N	N	N	N	N	N
QPPV Location	Y	N	N	N	Y	Y	Y	N	Y	Y	Y	N	Y ⁽⁶⁾	N	N	N	N	N	N	N
Package Description	Y	N	N	N	Y	Y	Y	N	Y	Y	Y	N	Y	N	N	N	Y	N	N	N
Legal Status for Supply	Y	N	N	N	Y	Y	Y	N	Y	Y	Y	N	Y	N	N	N	Y	N	N	N
Authorisation Procedure Type	Y	N	N	N	Y	Y	Y	N	Y	Y	N	N	Y	N	N	N	Y	N	N	N

UPD fields ⁸	Level 3												Level 2				Level 1			
	RCUD = Read, Create, Update, Delete																			
	Commission				Competent Authorities				Agency				Marketing authorisation holders				Public			
	R	C	U	D	R	C	U	D	R	C	U	D	R	C	U ⁽¹⁾	D	R	C	U	D
Procedure Number	Y	N	N	N	Y	Y	Y	N	Y	Y	N	N	Y	N	N	N	Y	N	N	N
Marketing Authorisation Date	Y	N	N	N	Y	Y	N	N	Y	Y	N	N	Y	N	N	N	Y	N	N	N
Authorisation Country	Y	N	N	N	Y	Y	N	N	Y	Y	N	N	Y	N	N	N	Y	N	N	N
Reference Member State	Y	N	N	N	Y	Y	Y	N	Y	Y	Y	N	Y	N	N	N	Y	N	N	N
Member States Concerned	Y	N	N	N	Y	Y	Y	N	Y	Y	Y	N	Y	N	N	N	Y	N	N	N
Legal Basis	Y	N	N	N	Y	Y	N	N	Y	Y	N	N	Y	N	N	N	Y	N	N	N
Authorisation Number	Y	N	N	N	Y	Y	Y	N	Y	Y	Y	N	Y	N	N	N	Y	N	N	N
Reference Product Identifier	Y	N	N	N	Y	Y	Y	N	Y	Y	Y	N	Y	N	N	N	Y	N	N	N
Source Product Identifier	Y	N	N	N	Y	Y	Y	N	Y	Y	Y	N	Y	N	N	N	Y	N	N	N
Responsible authority (Organisation)	Y	N	N	N	Y	Y	Y	N	Y	Y	Y	N	Y	N	N	N	Y	N	N	N
Procedural information for post-authorisation changes																				
Application Identifier	Y	N	N	N	Y	N	N	N	Y	N	N	N	Y ⁽⁶⁾	N	N	N	N	N	N	N
Procedure Number	Y	N	N	N	Y	Y	N	N	Y	Y	N	N	Y ⁽⁶⁾	Y ⁽⁶⁾	N	N	N	N	N	N
Responsible Authority	Y	N	N	N	Y	N	N	N	Y	N	N	N	Y ⁽⁶⁾	Y ⁽⁶⁾	N	N	N	N	N	N
Variation Classification Code	Y	N	N	N	Y	N	N	N	Y	N	N	N	Y ⁽⁶⁾	Y ⁽⁶⁾	N	N	N	N	N	N
Submission Comment	Y	N	N	N	Y	N	N	N	Y	N	N	N	Y ⁽⁶⁾	Y ⁽⁶⁾	N	N	N	N	N	N
Date of Submission	Y	N	N	N	Y	N	N	N	Y	N	N	N	Y ⁽⁶⁾	N	N	N	N	N	N	N
Decision	Y	N	N	N	Y	Y	N	N	Y	Y	N	N	Y ⁽⁶⁾	N	N	N	N	N	N	N
Date of Decision	Y	N	N	N	Y	N	N	N	Y	N	N	N	Y ⁽⁶⁾	N	N	N	N	N	N	N

UPD fields ⁸	Level 3												Level 2				Level 1			
	RCUD = Read, Create, Update, Delete																			
	Commission				Competent Authorities				Agency				Marketing authorisation holders				Public			
	R	C	U	D	R	C	U	D	R	C	U	D	R	C	U ⁽¹⁾	D	R	C	U	D
Author of Decision	Y	N	N	N	Y	N	N	N	Y	N	N	N	Y ⁽⁶⁾	N	N	N	N	N	N	N
Nullification comment	N	N	N	N	N	Y	N	N	Y ⁽⁴⁾	Y	N	N	N	N	N	N	N	N	N	N

- 260 (1) Marketing authorisation holders can request the update of some of these fields, by the relevant Competent Authorities, via a variation that does not require assessment; this
261 footnote reference will be added to all relevant fields once the Implementing Regulation on variations not requiring assessment has been adopted
262 (2) Only visible for batch release manufacturing sites
263 (3) Only veterinary medicinal products that have been authorised will be shown
264 (4) EMA Data Stewards can read this information
265 (5) For mutual recognition (MRP), decentralised (DCP) and repeat use procedures (RUP), the reference member state (RMS) is responsible for creating or updating the English
266 version of the documents
267 (6) Only visible to the marketing authorisation holder that owns that veterinary medicinal product